Femasys Secures CPT Code for Infertility Treatment, Paving Way for Reimbursement
Event summary
- Femasys received approval from the AMA CPT Editorial Panel for a new Category III CPT code covering FemaSeed Intratubal Insemination (ITI).
- The new code is expected to be publicly issued by the AMA with an effective date of January 1, 2027.
- The code aims to advance reimbursement strategy for FemaSeed, supporting broader clinical adoption and patient access.
- FemaSeed is a first-step infertility treatment designed to bridge the gap between IUI and IVF.
- Clinical trials showed FemaSeed achieved more than double the pregnancy rates of IUI.
The big picture
The approval of a new CPT code is a crucial, albeit incremental, step in the reimbursement process for novel medical procedures. Femasys's move signals a strategic shift towards broader adoption of its FemaSeed technology, which aims to disrupt the existing infertility treatment landscape dominated by IUI and IVF. The company's success hinges on its ability to navigate the complexities of reimbursement and provider adoption within a market estimated to affect millions of women annually.
What we're watching
- Reimbursement Adoption
- The speed at which insurance providers adopt the new CPT code will directly impact Femasys's ability to scale FemaSeed's commercialization and patient access.
- Clinical Uptake
- How quickly gynecologists integrate FemaSeed into their treatment protocols, and the impact of this adoption on overall pregnancy rates, will be key indicators of success.
- Competitive Landscape
- The emergence of competing intratubal insemination technologies or alternative infertility treatments could challenge Femasys's market position and pricing power.
Related topics